Market Overview

UPDATE: Benchmark Terminates Coverage on BioClinica Following Acquisition by JLL Partners

Share:

In a report published Monday, Benchmark Company analyst Raymond Myers terminated the firm's coverage of BioClinica (NASDAQ: BIOC).

In the report, Myers noted, “BioClinica announced it has completed its previously disclosed agreement with the private equity firm, JLL Partners, to acquire BioClinica for $7.25 per share. BIOC shares are no longer publicly listed. At the time of announcement this reflected 1.6x our forecast 2012 revenue of $77.4 million and was a 23% premium to the prior 90-day trading average. Our prior forecasts and rating should no longer be relied upon; our prior Hold rating reflected the limited upside to the agreed $7.25 transaction price.”

BioClinica closed on Friday at $7.25.

Latest Ratings for BIOC

DateFirmActionFromTo
Mar 2019Maxim GroupInitiates Coverage OnBuy
Jun 2017Chardan CapitalInitiates Coverage OnBuy
Nov 2016Feltl & Co.UpgradesHoldBuy

View More Analyst Ratings for BIOC
View the Latest Analyst Ratings

 

Related Articles (BIOC)

View Comments and Join the Discussion!

Posted-In: Benchmark Company JLL PartnersAnalyst Color Termination Analyst Ratings

Latest Ratings

StockFirmActionPT
ALRNH.C. WainwrightMaintains3.0
TDOCBerenbergDowngrades
SLLH.C. WainwrightReiterates1.7
AMRNGoldman SachsDowngrades4.0
MOSCredit SuisseMaintains20.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com